Tumor lysis syndrome. Bibliographic review at 90 years of its description
Abstract
Tumor lysis syndrome refers to the constellation of metabolic disturbances which was first described in medical literature in 1929; references to this syndrome have increased since the advent of chemotherapy in the 1960s. It has great clinical relevance since it is considered to be the most frequent oncological emergency and it is potentially fatal.
Since it was first mentioned 90 years ago, medical knowledge has broadened concerning the understanding of this pathophysiology; however, its definition, classification and therapeutic management are still discussed in various fields. It is essential to identify patients at risk early and start treatment quickly.
This study will provide an update and review of the subject with particular emphasis on those aspects which are still under discussion. Not having a clear definition could be the reason why there is not accurate information regarding the incidence of this syndrome and its clinical impact on the morbidity and mortality of patients suffering from this it.
How to cite this article:
Delgado MD, Cestari JJ,Lestón Tauret AH, Alemano G. Tumor lysis syndrome. Bibliographic review at 90 years of its description. Rev Nefrol Dial Traspl. 2018; 38(2):148-59.
References
Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149(4):578-86.
Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844-54.
Strauss PZ, Hamlin SK, Dang J. Tumor Lysis Syndrome: A Unique Solute Disturbance. Nurs Clin North Am. 2017;52(2):309-20.
Edeani A, Shirali A. Chapter 4: Tumor Lysis Syndrome. En: Onco-Nephrology Curriculum, Mark A. Perazella editor. Washington, D.C.: American Society of Nephrology, [2017].
Wilson FP, Berns JS. Onco-nephrology: tumor lysis syndrome. Clin J Am Soc Nephrol. 2012;7(10):1730-9.
Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis. 2014;21(1):18-26.
Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3-11.
Weeks AC, Kimple ME. Spontaneous Tumor Lysis Syndrome: A Case Report and Critical Evaluation of Current Diagnostic Criteria and Optimal Treatment Regimens. J Investig Med High Impact Case Rep. 2015;3(3):1-6.
Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med. 1993;94(2):133-9.
Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.
Levin A, Warnock DG, Mehta RL, Kellum JA, Shah SV, Molitoris BA, et al. Improving outcomes from acute kidney injury: report of an initiative. Am J Kidney Dis. 2007;50(1):1-4.
Hsu HH, Chan YL, Huang CC. Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure: clinical features and therapeutic approach. J Nephrol. 2004;17(1):50-6.
Alkhuja S, Ulrich H. Acute renal failure from spontaneous acute tumor lysis syndrome: a case report and review. Ren Fail. 2002;24(2):227-32.
Baeksgaard L, Sørensen JB. Acute tumor lysis syndrome in solid tumors, a case report and review of the literature. Cancer Chemother Pharmacol. 2003;51(3):187-92.
Mato AR, Riccio BE, Qin L, Heitjan DF, Carroll M, Loren A, et al. A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leuk Lymphoma. 2006;47(5):877-83.
Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H, Myint H, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma. 2003;44(1):77-83.
Seidemann K, Meyer U, Jansen P, Yakisan E, Rieske K, Führer M, et al. Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin's lymphoma and B-ALL. Observations from the BFM-trials. Klin Padiatr. 1998;210(4):279-84.
Montesinos P, Lorenzo I, Martín G, Sanz J, Pérez-Sirvent ML, Martínez D, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93(1):67-74.
Darmon M, Guichard I, Vincent F, Schlemmer B, Azoulay E. Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma. 2010;51(2):221-7.
Tosi P, Barosi G, Lazzaro C, Liso V, Marchetti M, Morra E, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica. 2008;93(12):1877-85.
Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767-78.
Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone, results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207-13.
Cheuk DK, Chiang AK, Chan GC, Ha SY. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cochrane Database Syst Rev. 2014;(8):CD006945.
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-94.
Jones GL, Will A, Jackson GH, Webb NJ, Rule S; British Committee for Standards in Haematology. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015;169(5):661-71.
